Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo and Roche.

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

[59] Thus, there are not enough data to support the use of HER2 as a prognostic marker, or as a predictor for specific chemotherapy protocols/endocrine therapy or for routine detection of serum ...